Alterations of serum Th1 and Th2 chemokines by combination therapy of interferon-γ and narrowband UVB in patients with mycosis fungoides

Journal of Dermatological Science

Volumn 50, Issue 3, 2008, Pages 217-225

  Shimauchi, Takatoshi ^a   Sugita, Kazunari ^a   Nishio, Daisuke ^a   Isoda, Hideka ^a   Abe, Shoko ^a   Yamada, Yoko ^a   Hino, Ryosuke ^a   Ogata, Makiko ^a   Kabashima, Kenji ^a   Tokura, Yoshiki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Chemokine; IFN ; Mycosis fungoides; Narrowband UVB

Indexed keywords

BIOGAMMA; CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE DERIVED CHEMOKINE; O GAMMA 100; RECOMBINANT GAMMA INTERFERON; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MYCOSIS FUNGOIDES; PHOTOTHERAPY; PRIORITY JOURNAL; ULTRAVIOLET B RADIATION;

AGED; AGED, 80 AND OVER; CHEMOKINE CCL17; CHEMOKINE CCL22; CHEMOKINE CXCL10; CHEMOKINE CXCL9; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERFERON TYPE II; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; SKIN NEOPLASMS; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 42649137905     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2007.12.004     Document Type: Article

References (32)

1. Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3785
2. Vowels B.R., Lessin S.R., Cassin M., Jaworsky C., Benoit B., Wolfe J.T., and Rook A.H. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 103 (1994) 669-673
3. Noorduyn L.A., Beljaards R.C., Pals S.T., van Heerde P., Radaszkiewicz T., Willemze R., and Meijer C.J. Differential expression of the HECA-452 antigen (cutaneous lymphocyte-associated antigen, CLA) in cutaneous and non-cutaneous T-cell lymphomas. Histopathology 21 (1992) 59-64
4. Berger C.L., Wang N., Christensen I., Longley J., Heald P., and Edelson R.L. The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 107 (1996) 392-397
5. Seo N., Tokura Y., Matsumoto K., Furukawa F., and Takigawa M. Tumor-specific cytotoxic T lymphocyte activity in Th2-type Sezary syndrome: its enhancement by interferon-γ (IFN-γ) and IL-12 and fluctuations in association with disease activity. Clin Exp Immunol 112 (1998) 403-409
6. Ishihara K., Ikeda S., Mori S., Urabe H., and Arao R. Phase II study of recombinant human interferon γ (SUN4800) for cutaneous malignancies. Nishinihon Hifuka 51 (1989) 766-775
7. Kaplan E.H., Rosen S.T., Norris D.B., Roenigk Jr. H.H., Saks S.R., and Bunn Jr. P.A. Phase II study of recombinant human interferon γ for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82 (1990) 208-212
8. Parrish J.A., and Jaenicke K.F. Action spectrum for phototherapy of psoriasis. J Invest Dermatol 76 (1981) 359-362
9. Gathers R.C., Scherschun L., Malick F., Fivenson D.P., and Lim H.W. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol 47 (2002) 191-197
10. Diederen P.V., van Weelden H., Sanders C.J., Toonstra J., and van Vloten W.A. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 48 (2003) 215-219
11. + lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol 115 (2000) 640-646
12. Hirata H., Arima M., Cheng G., Honda K., Fukushima F., Yoshida N., Eda F., and Fukuda T. Production of TARC and MDC by naïve T cells in asthmatic patients. J Clin Immunol 23 (2003) 34-45
13. Imai T., Baba M., Nishimura M., Kakizaki M., Takagi S., and Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 272 (1997) 15036-15047
14. Imai T., Chantry D., Raport C.J., Woods C.L., Nishimura M., Godiska R., Yoshie O., and Gray P.W. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J Biol Chem 273 (1998) 1764-1768
15. Sallusto F., Lenig D., Mackay C.R., and Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187 (1998) 875-883
16. Cole K.E., Strick C.A., Paradis T.J., et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187 (1998) 2009-2021
17. Loetscher M., Gerber B., Loetscher P., Jones S.A., Clark-Lewis I., Baggiolini M., and Moser B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184 (1996) 963-969
18. Ferenczi K., Fuhlbrigge R.C., Pinkus J.L., Pinkus G.S., and Kupper T.S. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 119 (2002) 1405-1410
19. Kakinuma T., Sugaya M., Nakamura K., Kaneko F., Wakugawa M., Matsushima K., and Tamaki K. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 48 (2003) 23-30
20. Kallinich T., Muche J.M., Qin S., Sterry W., Audring H., and Kroczek R.A. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol 121 (2003) 1045-1052
21. Yamaguchi T., Ohshima K., Tsuchiya T., Suehuji H., Karube K., Nakayama J., Suzumiya J., Yoshino T., and Kikuchi M. The comparison of expression of cutaneous lymphocyte-associated antigen (CLA), and Th1- and Th2- associated antigens in mycosis fungoides and cutaneous lesions of adult T-cell leukemia/lymphoma. Eur J Dermatol 13 (2003) 553-559
22. Lu D., Duvic M., Medeiros L., Luthra R., Dorfman D.M., and Jones D. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol 115 (2001) 413-421
23. Shimauchi T., Kabashima K., and Tokura Y. CXCR3 and CCR4 double positive tumor cells in granulomatous mycosis fungoides. J Am Acad Dermatol 54 (2006) 1109-1111
24. Yagi H., Seo N., Ohshima A., Itoh N., Horibe T., Yoshinari Y., Takigawa M., and Hashizume H. Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay. Am J Surg Pathol 30 (2006) 1111-1119
25. Hino R., Shimauchi T., and Tokura Y. Treatment with IFN-γ increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides. J Dermatol Sci 38 (2005) 189-195
26. Hino R., Kobayashi M., Mori T., Orimo H., Shimauchi T., Kabashima K., and Tokura Y. Inhibition of T helper 2 chemokine production by narrowband ultraviolet B in cultured keratinocytes. Br J Dermatol 156 (2007) 830-837
27. Kim E.J., Hess S., Richardson S.K., et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115 (2005) 798-812
28. Vonderheid E.C., Bernengo M.G., Burg G., et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46 (2002) 95-106
29. Clark C., Dawe R., Evans A., Lowe G., and Ferguson J. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol 136 (2000) 748-752
30. Papadavid E., Economidou J., Psarra A., et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 148 (2003) 709-718
31. Tensen C.P., Vermeer M.H., van der Stoop P.M., van Beek P., Scheper R.J., Boorsma D.M., and Willemze R. Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas. J Invest Dermatol 111 (1998) 222-226
32. Masui Y., Sugaya M., Kagami S., et al. Sezary syndrome treated with narrowband ultraviolet B: time-course measurement of serum levels of CCL17/27. Clin Exp Dermatol 32 (2007) 57-59